Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Glucose Transporter Glut6 CRISPR/Cas9 KO Plasmid (h): sc-406852
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Glucose Transporter Glut6 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Glucose Transporter Glut6 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Glucose Transporter Glut6 Antibody (B-3): sc-373973
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Glucose Transporter Glut6 CRISPR/Cas9 KO Plasmid (h) | sc-406852 | 20 µg | $397.00 |
Overview
SLC2A6 encodes Glucose Transporter Glut6 (GLUT6), a facilitative hexose transporter of the SLC2 family that supports cellular glucose uptake and metabolic substrate availability. GLUT6 expression is enriched in immune and hematopoietic lineages and is responsive to activation cues, linking it to shifts in glycolysis, oxidative phosphorylation, and broader immunometabolic programs. Through its role in controlling intracellular carbohydrate flux, GLUT6 can influence redox balance, biosynthetic pathways, and signaling nodes such as AMPK and mTOR that couple nutrient status to cell growth and survival. Dysregulated SLC2A6 expression has been reported in inflammatory contexts and multiple cancers, motivating mechanistic studies of how altered glucose transport rewires tumor and immune cell metabolism.
Glucose Transporter Glut6 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the SLC2A6 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the SLC2A6 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the SLC2A6 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Glucose Transporter Glut6 protein expression.
This CRISPR knockout system enables efficient generation of SLC2A6-deficient cell models for investigation of Glucose Transporter Glut6 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting SLC2A6 exon(s) critical for Glucose Transporter Glut6 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple SLC2A6 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Glucose Transporter Glut6 CRISPR/Cas9 KO Plasmid (h) and Glucose Transporter Glut6 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the SLC2A6 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Glucose Transporter Glut6 HDR Plasmid (h) and Glucose Transporter Glut6 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by SLC2A6 homology arms to support homology-directed repair at defined SLC2A6 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.